Fasedienol Nasal Spray Modestly Reduces Public Speaking Distress in Social Anxiety
This phase 3 abstract reports the first randomized efficacy signal for an intranasal, non-systemic, as-needed agent in social anxiety disorder (SAD), a setting where pharmacists mostly manage daily serotonergic agents, beta-blockers, and benzodiazepines.
📅 Journal publication: Oct 2024(online Jan 10, 2025)·Last updated: Nov 12, 2026
Fasedienol nasal spray shows promise for rapid relief in social anxiety.
Fasedienol nasal spray offers a potential new treatment for social anxiety disorder (SAD) with a rapid onset of action. Fasedienol showed a greater reduction in distress scores and improvement in global impressions compared to placebo, with significant results (p=0.015, p=0.033, p=0.003). While promising, this phase 3 data is preliminary. Pharmacists should note its non-systemic action and potential rapid efficacy for SAD. Fasedienol nasal spray could become a novel, rapid-acting treatment for social anxiety disorder.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Liebowitz MR, Salmán E, Hanover R, Reed B, Baker RA, Monti L
Citation:Liebowitz MR, Salmán E, Hanover R, et al. Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder (SAD). CNS spectrums. 2024;29(5):523-524. doi:10.1017/S1092852924002049